沙库巴曲缬沙坦钠片对射血分数保留心力衰竭患者心功能及氧化应激指标的影响

Effects of Sacubitril Valsartan Sodium Tablets on Cardiac Function and Oxidative Stress Indexes in Patients with Heart Failure with Preserved Ejection Fraction

目的:探究沙库巴曲缬沙坦钠片对射血分数保留心力衰竭(HFpEF)患者心功能及氧化应激指标的影响。方法:纳入2020年8月-2021年12月赣南医学院第一附属医院心血管内科收治的HFpEF患者80例,按随机数字表法将其分为两组,各40例。对照组采用贝那普利片治疗,研究组在对照组的基础上联合沙库巴曲缬沙坦钠片治疗。对比两组临床疗效、心功能[二尖瓣舒张早期流速峰值(E)、舒张早期二尖瓣环运动速度(e’)、E/二尖瓣舒张晚期流速峰值(E/A)、E/e’]指标、6分钟步行试验距离(6MWT)、血清N末端B型利钠肽前体(NT-proBNP)、氧化应激[一氧化氮(NO)、超氧化物歧化酶(SOD)、丙二醛(MDA)]指标、生活质量评分、不良反应发生情况。结果:研究组治疗总有效率为95.00%,高于对照组的77.50%(P<0.05);治疗后,研究组E、e’水平均高于对照组,E/A、E/e’、NT-proBNP均低于对照组,6MWT长于对照组(P<0.05);治疗后,研究组MDA、NO水平均低于对照组,SOD水平高于对照组(P<0.05);治疗后,研究组躯体状况、情绪变化、其他领域评分均低于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:沙库巴曲缬沙坦钠片在HFpEF患者治疗中获得较好的临床效果,可有效改善患者心功能各指标水平,并可减轻氧化应激反应,利于患者生活质量的提高,无明显不良反应,安全可靠,值得推广应用。

Objective:To investigate the effects of Sacubitril Valsartan Sodium Tablets on cardiac function and oxidative stress indexes in patients with heart failure with preserved ejection fraction(HFpEF).Method:A total of 80 patients with HFpEF admitted to Department of Cardiovascular Medicine,the First Affiliated Hospital of Gannan Medical University from August 2020 to December 2021 were enrolled and divided into two groups by random number table method,with 40 cases in each group.The control group was treated with Benazepril Tablets,and the study group was treated with Sacubitril Valsartan Sodium Tablets on the basis of the control group.The clinical efficacy,cardiac function indexes[peak value of early mitral diastolic flow(E),early diastolic mitral annulus velocity(e’),E/peak late diastolic flow rate of mitral valve(E/A),E/e’],6 min walking test distance(6MWT),serum N-terminal precursor B-type natriuretic peptide(NT-proBNP)and indicators of oxidative stress[nitric oxide(NO),superoxide dismutase(SOD),malondialdehyde(MDA)],quality of life scores and adverse reactions were compared between two groups.Result:The total effective rate in study group was 95.00%,higher than 77.50%in control group(P<0.05);after treatment,the levels of E and e’in the study group were higher than those in the control group,E/A,E/e’and NT-proBNP were lower than those in the control group,and 6MWT was longer than that in the control group(P<0.05);after treatment,the levels of MDA and NO in the study group were lower than those in the control group,and the level of SOD in the study group was higher than that in the control group(P<0.05);after treatment,the physical condition,emotional changes and scores of other fields in the study group were lower than those in the control group,the differences were statistically significant(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Sacubitril Valsartan Sodium Tablets have achieved good clinical effect in patients with HFpEF,it can effectively improve the levels of cardiac function indicators and reduce oxidative stress reaction,which is conducive to the improvement of patients’quality of life,without obvious adverse reactions,safe and reliable,worthy of popularization and application.